Induction of cytochrome P450 (CYP) enzymes by xenobiotics is a major concern in clinical practice because of the potential for drug-associated attenuated efficacy, or increased metabolite-associated toxicity, in the presence of concomitantly administered drugs. CYP2B6 is a highly-inducible enzyme in human liver. Recent studies have shown that the relative contribution of CYP2B6 to hepatic CYP content and substrate metabolism are much higher than estimated previously, and suggest that induction of this enzyme may be of therapeutic importance. The long-term objective of this ongoing project is to elucidate the molecular mechanisms governing drug-induced regulation of human hepatic CYP2B6. Results from the current funding period established human (h) PXR as a major transcriptional factor capable of regulating CYP2B6 induction by many compounds. Although it is widely accepted that CAR mediates induction of rodent CYP2B genes, the role of hCAR in human CYP2B6 regulation is far from clear, and direct extrapolation of rodent data to humans is risky due to obvious species differences. The central hypothesis of the proposed studies is that hCAR plays a distinct role compared with hPXR in human CYP2B6 induction, and differs from hPXR in its preferred induction of CYP2B6 over CYP3A4.
The specific aims of the proposed studies are to: 1) define the role of hCAR in the regulation of hepatic CYP2B6 expression, 2) elucidate the molecular mechanisms of differential regulation of CYP2B6 and CYP3A4 by hCAR, 3) characterize the differences between direct and indirect hCAR activators in the mechanisms of hCAR nuclear activation and CYP2B6 induction, and 4) assess the utility of selective hCAR activators to facilitate cyclophosphamide therapeutic activation. A multifaceted experimental approach incorporating protein-protein and protein-DNA binding assays, transfection and hCAR translocation assays in immortalized cell lines and/or human primary hepatocytes, siRNA knockdown of hCAR and hPXR in human hepatocytes, and transient in vivo expression of hCAR in CAR-/- mice will be employed to delineate the overlapping and distinct roles of hCAR versus hPXR in CYP2B6 induction, to compare indirect and direct mechanisms of hCAR nuclear activation and their impact on CYP2B6 induction, and to evaluate the roles of selective hCAR activators in facilitating cyclophosphamide (CPA) bioactivation. Data generated from the proposed in vitro and in vivo studies will provide important insight into the molecular mechanisms of CYP2B6 induction in humans, allowing for improved prediction of drug-drug interactions. In addition, these studies will explore selective modulation of drug metabolism via hCAR-mediated CYP2B6 induction as a means to increase therapeutic efficacy and decrease toxicity of a model CYP2B6 substrate, CPA. ? ? ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK061652-06
Application #
7414044
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Serrano, Jose
Project Start
2002-04-01
Project End
2011-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
6
Fiscal Year
2008
Total Cost
$298,337
Indirect Cost
Name
University of Maryland Baltimore
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Mackowiak, Bryan; Li, Linhao; Welch, Matthew A et al. (2017) Molecular Basis of Metabolism-Mediated Conversion of PK11195 from an Antagonist to an Agonist of the Constitutive Androstane Receptor. Mol Pharmacol 92:75-87
Zuo, Rongjun; Li, Feng; Parikh, Sweta et al. (2017) Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach. Drug Metab Dispos 45:198-207
Lynch, Caitlin; Zhao, Jinghua; Wang, Hongbing et al. (2016) Quantitative High-Throughput Luciferase Screening in Identifying CAR Modulators. Methods Mol Biol 1473:33-42
Hedrich, William D; Xiao, Jingwei; Heyward, Scott et al. (2016) Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment. Mol Cancer Ther 15:392-401
Li, Linhao; Li, Daochuan; Heyward, Scott et al. (2016) Transcriptional Regulation of CYP2B6 Expression by Hepatocyte Nuclear Factor 3? in Human Liver Cells. PLoS One 11:e0150587
Mackowiak, Bryan; Wang, Hongbing (2016) Mechanisms of xenobiotic receptor activation: Direct vs. indirect. Biochim Biophys Acta 1859:1130-1140
Hedrich, William D; Hassan, Hazem E; Wang, Hongbing (2016) Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B 6:413-425
Fahmi, Odette A; Shebley, Mohamad; Palamanda, Jairam et al. (2016) Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective. Drug Metab Dispos 44:1720-30
Jackson, Jonathan P; Li, Linhou; Chamberlain, Erica D et al. (2016) Contextualizing Hepatocyte Functionality of Cryopreserved HepaRG Cell Cultures. Drug Metab Dispos 44:1463-79
Lynch, Caitlin; Zhao, Jinghua; Huang, Ruili et al. (2015) Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor. Sci Rep 5:10405

Showing the most recent 10 out of 48 publications